First-line therapy with tyrosine kinase inhibitors (TKI) targeting the respective gene mutations is usually recommended for NSCLC with driver gene mutations such as the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF, and ROS1 genes. Here, ALK is linked to non-small cell lung carcinoma.